Our data would suggest that inhibition of hedgehog signaling would reduce plaque development, and several hedgehog pathway inhibitors exist, including the SMO antagonists vismodegib and sonidegib, which have US Food and Drug Administration approval for treatment of basal cell carcinoma.49,50 Directly targeting HHIPL1 might also represent a promising option for therapy. This evidence concerns the gene HHIPL1 and basal cell carcinoma.